Effect of golimumab on endothelial vasomotor function and arterial stiffness in ankylosing spondylitis

Objective: to evaluate the effect of golimumab (GLM) on endothelial vasomotor function and arterial stiffness in patients with ankylosing spondylitis (AS).

Subjects and methods. A total of 42 patients with advanced-stage AS, who were older than 18 years and met the 1984 modified New York criteria with a disease duration of ≤5 years, were examined. The investigators visualized carotid arteries to determine local vascular wall stiffness, studied regional arterial stiffness to assess a pulse wave contour analysis, and a reactive hyperemia test before and after 104-week therapy.

Results and discussion. RA patients without cardiovascular comorbidity were found to have signs of subclinical great artery involvement accompanied by endothelial vasoregulatory dysfunction in both the small resistance and large muscular arteries; by increases in common carotid artery (CCA) intima-media thickness (IMT) and stiffness index (SI); by rises in peripheral augmentation index (AIp), SI and reflection index (RI), the intensity of a change in which correlated with disease duration and activity assessed by ASDAS; as well as with the modified Schober test value, cervical rotation, and tragus-to-wall distance. In addition to a decrease in the Ankylosing Spondylitis Disease Activity Score (ASDAS), GML treatment in patients with AS caused a statistically significant increase in the amplitude occlusion index to the control values and a rise in the phase shift between the channels by an average of 2 times (p<0.01) as compared to the baseline values; a decrease in CCA IMT by an average by 20% (p=0.01) and in the local stiffness of the (carotid) vascular bed by 31% (p=0.01). The pulse wave contour analysis after 104-week GLM therapy revealed that AIp, SI and RI decreased by an average of 5 (р<0.001), 1.3 (р<0.01), and 2 (p<0.05) times, respectively, with the remaining statistically significant differences from the control values.

Conclusion. In addition to the effectively reduced inflammatory activity, GLM therapy in patients with AS provides restoration of endothelial function in both the small resistance vessels (an increase in the amplitude occlusion index) and the large muscular arteries (a rise in the phase shift between the channels) and also has a vasoprotective effect on the wall of large elastic vessels (reductions in CCA IMT, SI, AIp, and SI) and small muscular arteries (a decrease in RI).

1. Насонов ЕЛ, редактор. Российские клинические рекомендации. Ревматология. Москва: ГЭОТАР-Медиа; 2017. 464 с. [Nasonov EL, editor. Rossiiskie klinicheskie rekomendatsii. Revmatologiya [Russian clinical recommendations. Rheumatology]. Moscow: GEOTAR-Media; 2017. 464 p.].

2. Papagoras C, Voulgari PV, Drosos AA. Atherosclerosis and cardiovascular disease in the spondyloarthritides, particularly ankylosing spondylitis and psoriatic arthritis. Clin Exp Rheumatol. 2013;31:612-20. 3. Gonzalez-Juanatey C, Vazquez-Rodriguez TR, Miranda-Filloy JA, et al. The high prevalence of subclinical atherosclerosis in patients with ankylosing spondylitis without clinically evident cardiovascular disease. Medicine (Baltimore). 2009;88:358-65. doi: 10.1097/MD.0b013e3181c10773

3. Peters MJ, van Eijk IC, Smulders YM, et al. Signs of accelerated preclinical atherosclerosis in patients with ankylosing spondylitis. J Rheumatol. 2010;37:161-6. doi: 10.3899/jrheum.090667

4. Heslinga SC, van den Oever IA, van Sijl AM, et al. Cardiovascular risk management in patients with active ankylosing spondylitis: a detailed evaluation. BMC Musculoskelet Disord. 2015 Apr 9;16:80. doi: 10.1186/s12891-015-0532-3

5. Eriksson JK, Jacobsson L, Bengtsson K, Askling J. Is ankylosing spondylitis a risk factor for cardiovascular disease, and how do these risks compare with those in rheumatoid arthritis? Ann Rheum Dis. 2017 Feb;76(2):364-70. doi: 10.1136/annrheumdis-2016-209315

6. Bakland G, Gran JT, Nossent JC. Increased mortality in ankylosing spondylitis is related to disease activity. Ann Rheum Dis 2011;70:1921-5. doi: 10.1136/ard.2011.151191

7. Atzeni F, Dorea A, Nurmohamed M, Pauletto P. The Heart in Systemic Autoimmune Diseases. Handbook of Systemic Autoimmune Diseases. 2017. Vol. 14. ISBN: 978-0-12-803997-7

8. Haroon NN, Paterson JM, Li P, et al. Patients with ankylosing spondylitis have increased cardiovascular and cerebrovascular mortality. A population-based study. Ann Intern Med. 2015 Sep 15;163(6):409-16. doi: 10.7326/M14-2470

9. Mathieu S, Gossec L, Dougados M, Soubrier M. Cardiovascular profile in ankylosing spondylitis: a systematic review and meta-analysis. Arthritis Care Res (Hoboken). 2011;63:557-63. doi: 10.1002/acr.20364

10. Libby P, Ridker PM, Hansson GK. Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol. 2009;54:2129-38. doi: 10.1016/j.jacc.2009.09.009

11. Davidson MH, Toth PP. High-density lipoprotein metabolism: potential therapeutic targets. Am J Cardiol. 2007;100:32-40. doi: 10.1016/j.amjcard.2007.08.011

12. Divecha H, Sattar N, Rumley A, et al. Cardiovascular risk parameters in men with ankylosing spondylitis in comparison with noninflammatory control subjects: relevance of systemic inflammation. Clin Sci (Lond). 2005;109:171-6. doi: 10.1042/CS20040326

13. Szabo SM, Levy AR, Rao SR, et al. Increased risk of cardiovascular and cerebrovascular diseases in individuals with ankylosing spondylitis: a population-based study. Arthritis Rheum. 2011;63:3294-304. doi: 10.1002/art.30581

14. Maia DG, Augusto KL, Bezerra MC, Rodrigues CEM. Metabolic syndrome in patients with ankylosing spondylitis receiving anti-TNFα therapy: association with predictors of cardiovascular risk. Clin Rheumatol. 2017;36(10):2371-6. doi: 10.1007/s10067-017-3623-8

15. Arida A, Protogerou AD, Konstantonis G, et al. Subclinical atherosclerosis is not accelerated in patients with ankylosing spondylitis with low disease activity: new data and metaanalysis of published studies. J Rheumatol. 2015;42(11):2098-105. doi: 10.3899/jrheum.150316

16. Bodnar N, Kerekes G, Seres I, et al. Assessment of subclinical vascular disease associated with ankylosing spondylitis. J Rheumatol. 2011;38(4):723-9. doi: 10.3899/jrheum.100668

17. Yuan Y, Yang J, Zhang X, et al. Carotid Intima-Media Thickness in Patients with Ankylosing Spondylitis: A Systematic Review and Updated Meta-Analysis. J Atheroscler Thromb. 2018;25:000-000. doi: 10.5551/jat.45294

18. Tam LS, Shang Q, Kun EW, et al. The effects of golimumab on subclinical atherosclerosis and arterial stiffness in ankylosing spondylitis – a randomized, placebo-controlled pilot trial. Rheumatology (Oxford). 2014;53:1065-74. doi: 10.1093/rheumatology/ket469

19. Van Eijk IC, Peters MJ, Serne EH, et al. Microvascular function is impaired in ankylosing spondylitis and improves after tumour necrosis factor alpha blockade. Ann Rheum Dis. 2009;68:362-6. doi: 10.1136/ard.2007.086777

20. Van Sijl AM, van Eijk IC, Peters MJL, et al. Tumour necrosis factor blocking agents and progression of subclinical atherosclerosis in patients with ankylosing spondylitis. Ann Rheum Dis. 2015;74:119-23. doi: 10.1136/annrheumdis-2013-203934

21. Angel K, Provan SA, Gulseth HL, et al. Tumor necrosis factor-α antagonists improve aortic stiffness in patients with inflammatory arthropathies: a controlled study. Hypertension. 2010;55:333-8. doi: 10.1161/HYPERTENSIONAHA.109.143982

22. Van der Heijde D, Ramiro S, Landewe R, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis. 2017;76(6):978-91. doi: 10.1136/annrheumdis-2016-210770

23. Mathieu S, Joly H, Baron G, et al. Trend towards increased arterial stiffness or intima-media thickness in ankylosing spondylitis patients without clinically evident cardiovascular disease. Rheumatology (Oxford). 2008;47:1203-7. doi: 10.1093/rheumatology/ken198

24. Capkin E, Karkucak M, Kiris A, et al. Anti-TNF-alpha therapy may not improve arterial stiffness in patients with AS: a 24-week follow-up. Rheumatology (Oxford). 2012;51:910-4. doi: 10.1093/rheumatology/ker434

25. Mathieu S, Pereira B, Couderc M, et al. No significant changes in arterial stiffness in patients with ankylosing spondylitis after tumour necrosis factor alpha blockade treatment for 6 and 12 months. Rheumatology (Oxford). 2013;52:204-9. doi: 10.1093/rheumatology/kes272

26. Кардиоваскулярная профилактика: национальные рекомендации. Кардиоваскулярная терапия и профилактика. 2011;10(Прил. 2):64 с. [Cardiovascular prevention: national guidelines. Cardiovascular therapy and prevention. 2011;10(Suppl. 2): 64 p. (In Russ).].

27. Kawasaki T, Sasayama S, Yagi S. Noninvаsive meаsurement of the age related changes in stiffness if major branches of the human arteries. Cardiovasc Res. 1987;144:345-52.

28. Парфeнов АС. Экспресс-диагностика сердечно-сосудистых заболеваний. Мир измерений. 2008;(6):74-82 [Parfenov AS. Express diagnostics of cardiovascular diseases. Mir Izmerenii. 2008;(6):74-82 (In Russ.)].

29. Гайдукова ИЗ, Ребров АП, Лапшина СА и др. Применение нестероидных противовоспалительных препаратов и генно-инженерных биологических препаратов для лечения аксиальных спондилоартритов. Рекомендации Экспертной группы по изучению спондилоартритов при Общероссийской общественной организации «Ассоциация ревматологов России». Научно-практическая ревматология. 2017;55(5):474-84 [Gaidukova IZ, Rebrov AP, Lapshina SA, et al. Use of nonsteroidal anti-inflammatory drugs and biological agents for the treatment of axial spondyloarthritides. Recommendations of the Spondyloarthritis Study Group of Experts, All-Russian Public Organization «The Association of Rheumatology of Russia». Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2017;55(5):474-84 (In Russ.)]. doi: 10.14412/1995-4484-2017-474-484

30. Maxwell LJ, Zochling J, Boonen A, et al. TNF-alpha inhibitors for ankylosing spondylitis. Cochrane Database Syst Rev. 2015;4(4):CD005468. doi: 10.1002/14651858.CD005468.pub2

31. Чичасова НВ. Значение иммуногенности при лечении ревматических заболеваний ингибиторами фактора некроза опухоли α. Современная ревматология. 2015;9(4):4-12 [Chichasova NV. Value of immunogenicity in the TNF-α inhibitor treatment of rheumatic diseases. Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2015;9(4):4-12 (In Russ.)]. doi: 10.14412/1996-7012-2015-4-4-12

32. Каратеев ДЕ. Факторы, определяющие длительный успех терапии генно-инженерными биологическими препаратами при ревматоидном артрите. Современная ревматология. 2015;9(3):54-60 [Karateev DE. Factors determining long-term success of biologic therapy in rheumatoid arthritis. Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2015;9(3):54-60 (In Russ.)]. doi: 10.14412/1996-7012-2015-3-54-60

33. Inzinger M, Wippel-Slupetzky K, Weger W, et al. Survival and effectiveness of tumour necrosis factor-alpha inhibitors in the treatment of plaque psoriasis under daily life conditions: Report from the Psoriasis Registry Austria. Acta Derm Venereol. 2016;96:207-12. doi: 10.2340/00015555-2214

34. Tracey D, Klareskog L, Sasso EH, et al. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther. 2008 Feb;117(2):244-79. doi: 10. 1016/j.pharmthera.2007.10.001